Bio-Thera Solutions and Biomm have entered a licensing and supply agreement for Bio-Thera’s BAT2206, a ustekinumab biosimilar.
GUANGZHOU, China--(BUSINESS WIRE)--Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, today announced the company has entered into a licensing and supply agreement with Biomm SA, for BAT2206, its ustekinumab biosimilar, under which Biomm will have exclusive rights to distribute and market the drug in Brazil. Bio-Thera and Biomm’s partnership was initiated around a licensing and supply agreement for Biomm to distribute and market BAT1706, a bevacizumab biosimilar, in Brazil.
Global pharma major, Lupin Limited announced that they have entered into an distribution and marketing agreement with Biomm SA in Brazil.